Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for $30 million upfront. Modifi Biosciences shareholders are also eligible to ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

Uché Blackstock, Adrelia Allen, and Ai-jen Poo gathered at the TIME100 Health Leadership Forum in New York City on Oct. 22 to ...

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer aft ...

Standigm uses Synthia Retrosynthesis Software from Merck KGaA, Darmstadt, Germany, to accelerate its drug design and synthesis processes driving advancements in pharmaceutical development. Standigm ...

Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat. Find out why ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...